GSFs Reduce Infection Risk in Solid Tumors but May Not Improve Survival
Medicines that boost white blood cell production likely reduce infections after chemotherapy for solid tumors, and they probably increase the risk of bone pain.
People with solid tumors who received primary preventative granulopoiesis-stimulating factors after chemotherapy probably had fewer infections, according to an evidence synthesis current to June 2025 published by cochrane.org.
Key Clinical Takeaways:
- Primary preventative use of granulopoiesis-stimulating factors likely reduces infection risk in people receiving chemotherapy for solid tumors.
- The treatment probably causes a large increase in the risk of bone pain for these patients.
- The intervention likely results in little to no difference in overall survival rates or deaths from any cause during chemotherapy.
Treating Solid Tumors Involves Chemotherapy
Solid tumors represent approximately 90% of adult cancers and develop as solid masses in tissues such as the breasts, lungs, bones, and liver. Treating these cancers frequently involves chemotherapy regimens.
One unwanted effect of this treatment is bone marrow suppression, a process where the bone marrow slows or reduces the production of new blood cells. This suppression leads to neutropenia, which involves low levels of neutrophils, an infection-fighting white blood cell, thereby elevating infection risks and potentially reducing survival rates.
Granulopoiesis-stimulating factors can act as a supportive treatment alongside chemotherapy to increase white blood cell production. The two main types are granulocyte colony-stimulating factor, which mainly increases neutrophils, and granulocyte-macrophage colony-stimulating factor, which stimulates several infection-fighting blood cell types. Researchers examined whether giving these factors to prevent low white blood cell counts could improve disease control and reduce death rates compared to placebo or no preventative use.
Evidence From 26 Clinical Studies
The evaluation reviewed 26 studies involving a total of 5,320 participants with solid tumors across high- and middle-income countries. Compared with no preventative use, primary preventative use of granulopoiesis-stimulating factors after chemotherapy likely reduces the risk of infection, as shown across 7 studies involving 915 people, according to cochrane.org.
However, the evidence indicates that the treatment may result in little to no difference in overall survival, based on 3 studies with 537 people. Freedom from treatment failure also showed little to no difference based on 1 study of 259 people.
| Clinical Outcome | Number of Studies | Number of Participants | Observed Effect |
|---|---|---|---|
| Infection risk | 7 | 915 | Likely reduced |
| Overall survival | 3 | 537 | Little to no difference |
| Bone pain risk | 10 | 3,152 | Probably large increase |
| Death from any cause during chemotherapy | 11 | 3,001 | Likely little to no difference |
Preventing Factors May Increase Bone Pain
Primary preventative use of these factors probably results in a large increase in the risk of bone pain, according to data from 10 studies involving 3,152 participants. There is likely little to no difference between study groups regarding death from any cause during chemotherapy, based on 11 studies covering 3,001 people.
One study reported that individuals in the granulocyte colony-stimulating factor group experienced a longer average hospitalization duration of 9.7 days compared to 5.2 days for the control group. Quality of life was not reported in any of the included studies.
Confidence in the evidence ranged from moderate to low due to several methodological limitations. In some studies, participants, study personnel, and outcome assessors were aware of the assigned treatments. Results also varied widely across studies, and the trial sizes involved small numbers of participants across different types of solid tumors and varying doses.
It is unclear whether granulocyte-macrophage colony-stimulating factor provides similar benefits, and whether preventing low white blood cell counts helps patients live longer when both study groups receive identical chemotherapy regimens.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.